---
title: "Winning Health released its performance for the first three quarters, with a net loss attributable to the parent company of 241 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262898161.md"
description: "According to the Zhitong Finance APP, Winning Health released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.296 billion yuan, a year-on-year decrease of 32.27%. The net loss attributable to shareholders of the listed company was 241 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 228 million yuan. The basic loss per share was 0.1093 yuan"
datetime: "2025-10-27T12:23:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262898161.md)
  - [en](https://longbridge.com/en/news/262898161.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262898161.md)
generator: "portal-rs"
---

# Winning Health released its performance for the first three quarters, with a net loss attributable to the parent company of 241 million yuan

According to the Zhitong Finance APP, Winning Health (300253.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.296 billion yuan, a year-on-year decrease of 32.27%. The net loss attributable to shareholders of the listed company was 241 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 228 million yuan. The basic loss per share was 0.1093 yuan

### Related Stocks

- [300253.CN](https://longbridge.com/en/quote/300253.CN.md)

## Related News & Research

- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [CDC lifts beneficial stake in Exosens to 11.71% of capital, 13.87% of voting rights](https://longbridge.com/en/news/296499698.md)
- [JDC: Record growth in turnover and EBITDA, with strong outlook driven by new regulation and AI](https://longbridge.com/en/news/296247395.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [SpareBank 1 Østlandet employee share buyback offer book closes Aug. 20 at 16:00 CEST](https://longbridge.com/en/news/296449504.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**